{"id":4160,"date":"2025-07-22T10:27:29","date_gmt":"2025-07-22T07:27:29","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4160"},"modified":"2025-07-22T10:40:36","modified_gmt":"2025-07-22T07:40:36","slug":"sarepta-therapeutics-announces-pause-of-elevidys-shipments-in-the-usa","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/sarepta-therapeutics-announces-pause-of-elevidys-shipments-in-the-usa\/","title":{"rendered":"Sarepta Therapeutics anuncia la pausa en los env\u00edos de ELEVIDYS en EE. UU."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Hoy, Sarepta Therapeutics notific\u00f3 a la Administraci\u00f3n de Alimentos y Medicamentos de los EE. UU. (FDA) su decisi\u00f3n de pausar voluntaria y temporalmente todos los env\u00edos de ELEVIDYS (delandistr\u00f3geno moxeparvovec) para la distrofia muscular de Duchenne en los Estados Unidos, a partir del cierre de operaciones del martes 22 de julio de 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Hoy, Sarepta Therapeutics notific\u00f3 a la Administraci\u00f3n de Alimentos y Medicamentos de los EE. UU. (FDA) su decisi\u00f3n de pausar voluntaria y temporalmente todos los env\u00edos de ELEVIDYS (delandistr\u00f3geno moxeparvovec) para la distrofia muscular de Duchenne en los Estados Unidos, a partir del cierre de operaciones del martes 22 de julio de 2025.<\/p>","protected":false},"author":1,"featured_media":4164,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[33,65],"class_list":["post-4160","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevidys","tag-sarepta"],"subtitle":"La cuesti\u00f3n de seguridad que rodea al f\u00e1rmaco Elevidys para la distrofia muscular de Duchenne lleg\u00f3 a un punto tenso el viernes cuando la compa\u00f1\u00eda de biotecnolog\u00eda rechaz\u00f3 la solicitud de FDA de detener todos los env\u00edos de la terapia gen\u00e9tica en los EE. UU. FDA tambi\u00e9n revoc\u00f3 la designaci\u00f3n de plataforma para la tecnolog\u00eda de vector viral de Sarepta el viernes.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=4160"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/4160\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/4164"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=4160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=4160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=4160"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}